Abhinav V Reddy1, Colin S Hill1, Shuchi Sehgal1, Jin He2, Lei Zheng3, Joseph M Herman4, Jeffrey Meyer1, Amol K Narang1. 1. Department of Radiation Oncology & Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Sidney Kimmel Cancer Center, Baltimore, MD, USA. 2. Department of Surgery, Johns Hopkins University School of Medicine, Sidney Kimmel Cancer Center, Baltimore, MD, USA. 3. Department of Oncology, Johns Hopkins University School of Medicine, Sidney Kimmel Cancer Center, Baltimore, MD, USA. 4. Department of Radiation Oncology, Northwell Health, New Hyde Park, NY, USA.
Abstract
Background: To report on a cohort of radiation-naïve patients with pancreatic cancer who developed isolated local recurrence following surgical resection and were subsequently treated with stereotactic body radiation therapy (SBRT). Methods: Patients with pancreatic cancer who were treated with SBRT for isolated local recurrence after surgical resection were retrospectively reviewed. Clinical outcomes were calculated from completion of SBRT and included overall survival (OS), local progression-free survival (LPFS), distant metastasis-free survival (DMFS), and progression-free survival (PFS). Univariate (UVA) analysis was performed to identify variables associated with clinical outcomes. Kaplan-Meier method was used for survival outcomes. Toxicity was assessed using the Common Terminology Criteria for Adverse Events version 4.0. Results: From September 2012 to November 2018, a total of 19 patients with localized pancreatic cancer were treated with SBRT for isolated local recurrence after initial surgical resection. No patients had prior radiation. The median biologically effective dose (BED10) was 54.8 Gy (range, 37.5-54.8 Gy). Median OS was 17.1 months, with 6-month and 1-year OS rates of 94.4% and 69.6%, respectively. Nine patients (47.4%) developed local failure after SBRT. Pattern of first failure after SBRT was distant in 7 patients (46.7%), local in 5 patients (33.3%), and synchronous distant and local in 3 patients (20.0%). One patient developed local failure after developing distant disease first. Of the 9 local failures, 3 (33.3%) were out-of-field. Median LPFS was 22.2 months, with 6-month and 1-year LPFS rates of 86.9% and 63.2%, respectively. A BED10 <54.8 Gy was associated with inferior LPFS (1-year, 25.0% vs. 80.2%, P<0.009). Median DMFS and PFS were 15.6 months. There was 1 case (5.3 %) of grade 3 gastric perforation. There were no cases of grade 4-5 toxicity events. Conclusions: SBRT for locally recurrent pancreatic cancer after initial curative resection is safe and feasible. A BED10 <54.8 Gy was significantly associated with inferior local control. Further studies investigating dose escalation and optimal treatment volumes in the locally recurrent setting are warranted. 2022 Journal of Gastrointestinal Oncology. All rights reserved.
Background: To report on a cohort of radiation-naïve patients with pancreatic cancer who developed isolated local recurrence following surgical resection and were subsequently treated with stereotactic body radiation therapy (SBRT). Methods: Patients with pancreatic cancer who were treated with SBRT for isolated local recurrence after surgical resection were retrospectively reviewed. Clinical outcomes were calculated from completion of SBRT and included overall survival (OS), local progression-free survival (LPFS), distant metastasis-free survival (DMFS), and progression-free survival (PFS). Univariate (UVA) analysis was performed to identify variables associated with clinical outcomes. Kaplan-Meier method was used for survival outcomes. Toxicity was assessed using the Common Terminology Criteria for Adverse Events version 4.0. Results: From September 2012 to November 2018, a total of 19 patients with localized pancreatic cancer were treated with SBRT for isolated local recurrence after initial surgical resection. No patients had prior radiation. The median biologically effective dose (BED10) was 54.8 Gy (range, 37.5-54.8 Gy). Median OS was 17.1 months, with 6-month and 1-year OS rates of 94.4% and 69.6%, respectively. Nine patients (47.4%) developed local failure after SBRT. Pattern of first failure after SBRT was distant in 7 patients (46.7%), local in 5 patients (33.3%), and synchronous distant and local in 3 patients (20.0%). One patient developed local failure after developing distant disease first. Of the 9 local failures, 3 (33.3%) were out-of-field. Median LPFS was 22.2 months, with 6-month and 1-year LPFS rates of 86.9% and 63.2%, respectively. A BED10 <54.8 Gy was associated with inferior LPFS (1-year, 25.0% vs. 80.2%, P<0.009). Median DMFS and PFS were 15.6 months. There was 1 case (5.3 %) of grade 3 gastric perforation. There were no cases of grade 4-5 toxicity events. Conclusions: SBRT for locally recurrent pancreatic cancer after initial curative resection is safe and feasible. A BED10 <54.8 Gy was significantly associated with inferior local control. Further studies investigating dose escalation and optimal treatment volumes in the locally recurrent setting are warranted. 2022 Journal of Gastrointestinal Oncology. All rights reserved.
Entities:
Keywords:
Stereotactic body radiation therapy (SBRT); isolated local recurrence; locally recurrent pancreatic cancer; overall survival (OS); pancreatic ductal adenocarcinoma
Authors: Manisha Palta; Devon Godfrey; Karyn A Goodman; Sarah Hoffe; Laura A Dawson; David Dessert; William A Hall; Joseph M Herman; Alok A Khorana; Nipun Merchant; Arti Parekh; Caroline Patton; Joseph M Pepek; Joseph K Salama; Richard Tuli; Albert C Koong Journal: Pract Radiat Oncol Date: 2019 Sep - Oct
Authors: Andrew P Barbour; Jaswinder S Samra; Koroush S Haghighi; Mark W Donoghoe; Matthew Burge; Marion T Harris; Yu Jo Chua; Jenna Mitchell; Nick O'Rourke; Howard Chan; Val J Gebski; Sivakumar Gananadha; Daniel G Croagh; James G Kench; David Goldstein Journal: Ann Surg Oncol Date: 2020-01-29 Impact factor: 5.344
Authors: Sunil Krishnan; Awalpreet S Chadha; Yelin Suh; Hsiang-Chun Chen; Arvind Rao; Prajnan Das; Bruce D Minsky; Usama Mahmood; Marc E Delclos; Gabriel O Sawakuchi; Sam Beddar; Matthew H Katz; Jason B Fleming; Milind M Javle; Gauri R Varadhachary; Robert A Wolff; Christopher H Crane Journal: Int J Radiat Oncol Biol Phys Date: 2015-12-11 Impact factor: 7.038
Authors: Christine A Iacobuzio-Donahue; Baojin Fu; Shinichi Yachida; Mingde Luo; Hisashi Abe; Clark M Henderson; Felip Vilardell; Zheng Wang; Jesse W Keller; Priya Banerjee; Joseph M Herman; John L Cameron; Charles J Yeo; Marc K Halushka; James R Eshleman; Marian Raben; Alison P Klein; Ralph H Hruban; Manuel Hidalgo; Daniel Laheru Journal: J Clin Oncol Date: 2009-03-09 Impact factor: 44.544
Authors: Jacob A Miller; Diego A S Toesca; J Richelcyn M Baclay; Lucas K Vitzthum; Piotr Dubrowski; Erqi L Pollom; Daniel T Chang Journal: Int J Radiat Oncol Biol Phys Date: 2021-08-01 Impact factor: 7.038